Volta

Impact of COVID-19 on work loss in the United States- A retrospective database analysis

Unknown authors · 2024
hash_id: d7407546a8d7953cedc23656e8be6f4278f06c10252a69d4df5603fc79259bac · DOI: 10.1080/13696998.2024.2379056

Objectives This study investigates the utilization of work absence benefits among United States (US) employees diagnosed with COVID-19, examining frequency, duration, cost, and types of work loss benefits used.Methods This retrospective analysis of the Workpartners Research Reference Database (RRDb) included employees eligible for short- and long-term disability (STD and LTD employer-sponsored benefits, respectively), and other paid work absence benefits from 2018 to 2022. Workpartners RRDb includes over 3.5 million employees from over 500 self-insured employers across the US. Employees were identified by codes from adjudicated medical and disability claims for COVID-19 (2020–2022) and influenza, as well as prescription claims for COVID-19 treatments. Associated payments were quantified for each absence reason.Results Approximately 1 million employees were eligible for employer-sponsored paid leave …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (1)

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection secondary